Asked by: Christopher Chope (Conservative - Christchurch)
Question to the HM Treasury:
To ask the Chancellor of the Exchequer, how many responses were received to the consultation entitled Public Sector Exit Payments : A New Controls Process for High Exit Payments which closed on 17 October 2022; and for what reason a response has not yet been issued.
Answered by Laura Trott - Chief Secretary to the Treasury
The Government received 32 responses to the consultation on 'Public Sector Exit Payments: A New Controls Process for High Exit Payments'. HM Treasury will publish the government response in due course.
Asked by: Christopher Chope (Conservative - Christchurch)
Question to the Department for Environment, Food and Rural Affairs:
To ask the Secretary of State for Environment, Food and Rural Affairs, when he plans to write to the hon. Member for Christchurch on the Avon Valley footpath between Burton and Christchurch.
Answered by Robbie Moore - Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
Following our recent meeting on the Avon Valley footpath, I will write to the hon. Member shortly.
Asked by: Christopher Chope (Conservative - Christchurch)
Question to the Department for Environment, Food and Rural Affairs:
To ask the Secretary of State for Environment, Food and Rural Affairs, when he plans to write to the hon. Member for Christchurch on the potential impact of the level of phosphates in the River Avon on housing developments in Christchurch.
Answered by Robbie Moore - Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
I refer the hon. Member to my letter issued on 7 May 2024.
Asked by: Christopher Chope (Conservative - Christchurch)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether (a) his Department and (b) the Medicines and Healthcare products Regulatory Agency has received data from Astra Zeneca on the potential serious adverse effects of its covid-19 vaccine for a small number of recipients.
Answered by Maria Caulfield - Parliamentary Under Secretary of State (Department for Business and Trade) (Minister for Women)
The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.
Asked by: Christopher Chope (Conservative - Christchurch)
Question to the Ministry of Defence:
To ask the Secretary of State for Defence, pursuant to the Answer of 29 April 2024 to Question 23368 on Armed Forces: Mefloquine, how many of the common law claims have been resolved; and how many unresolved common law claims are the subject of continuing legal action.
Answered by Andrew Murrison - Parliamentary Under-Secretary (Ministry of Defence)
To date, 60 claims have been partially settled and three claims have been fully settled. Partially settled claims are those where damages have been agreed and paid to a Claimant, but where the Claimant's solicitor's costs remain in dispute.
A total of 457 claims are the subject of continuing legal action, in that they have not yet been resolved.
A trial has been listed for March 2025 to establish generic issues. At this trial 10 lead cases from the largest Claimant cohort will be heard. The trial means that all other claims are stayed until the outcome of the lead cases is decided.
Asked by: Christopher Chope (Conservative - Christchurch)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, with reference to the oral contribution by the Parliamentary Under Secretary of State at the Department of Health and Social Care during the debate on Covid-19: Response and Excess Deaths on Thursday 18 April 2024, Official Report, column 537, whether she has had recent discussions with (a) NICE and (b) the MHRA on their progress on reaching a decision on whether to recommend the use of Evusheld 2 to prevent covid-19.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The Department meets with the National Institute of Health and Care Excellence (NICE) regularly to discuss a range of issues, including access to medicines. The NICE has formally started its appraisal of AZD-3152, also known as sipavibart and referred to as Evusheld 2, ahead of the Medicines and Healthcare products Regulatory Agency’s (MHRA) decision on whether it should be given a United Kingdom marketing authorisation, and expects to invite stakeholder submissions in April 2024. Timelines for both the NICE’s guidance and licensing depend on data from the SUPERNOVA trial being available. AstraZeneca intends to submit clinical data to the NICE and the MHRA at the same time, with the aim that both organisations are able to reach decisions as close together as possible. If AZD-3152 is recommended as clinically and cost effective by the NICE, the National Health Service in England will be under a statutory requirement to fund AZD-3152 for eligible patients, in line with the NICE’s recommendations.
Asked by: Christopher Chope (Conservative - Christchurch)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how much the administration of the Vaccine Damage Payment Scheme cost the NHS Business Services Authority in (a) 2021, (b) 2022 and (c) 2023.
Answered by Maria Caulfield - Parliamentary Under Secretary of State (Department for Business and Trade) (Minister for Women)
The NHS Business Services Authority (NHSBSA) administers the Vaccine Damage Payment Scheme, on behalf of the Department. Administration costs for the scheme were £600,000, £8.8 million, and £16.1 million for April 2021 to March 2022, April 2022 to March 2023, and April 2023 to March 2024, respectively. Payments made by the NHSBSA for the provision of medical records totalled £1,200, £72,000, and £73,100, for the same periods. The figures are provided to the nearest decimal place.
Asked by: Christopher Chope (Conservative - Christchurch)
Question to the HM Treasury:
To ask the Chancellor of the Exchequer, what the total value was of (a) cigars, (b) snuff and (c) other tobacco products exported from the UK in (i) 2022 and (ii) 2023; and what were the principal countries of destination for those exports.
Answered by Nigel Huddleston - Financial Secretary (HM Treasury)
HM Revenue & Customs (HMRC) is responsible for the collection and publication of data on imports and exports of goods to and from the UK. HMRC releases this information monthly, as a National Statistic called the Overseas Trade in Goods Statistics (OTS), which is available via their dedicated website (www.uktradeinfo.com). From this website, it is possible to build your own data tables based upon bespoke search criteria.
Classification codes (according to the Harmonised System) are available to assist you in accessing published trade statistics data in the UK Global Tariff. Goods moving to and from the UK are identified by an eight-digit commodity code. These are publicly available from the UK Trade Tariff at https://www.gov.uk/trade-tariff.
The data on these exports and for other tobacco products can be obtained from www.uktradeinfo.com.
If you need help or support in constructing a table from the data on uktradeinfo, please contact uktradeinfo@hmrc.gov.uk.
Asked by: Christopher Chope (Conservative - Christchurch)
Question to the HM Treasury:
To ask the Chancellor of the Exchequer, what the value of imports of (a) vapes and (b) vaping equipment was in (i) 2022 and (ii) 2023; and what proportion of the total value of those imports came from China.
Answered by Nigel Huddleston - Financial Secretary (HM Treasury)
HM Revenue & Customs (HMRC) is responsible for the collection and publication of data on imports and exports of goods to and from the UK. HMRC releases this information monthly, as a National Statistic called the Overseas Trade in Goods Statistics (OTS), which is available via their dedicated website (www.uktradeinfo.com). From this website, it is possible to build your own data tables based upon bespoke search criteria.
Classification codes (according to the Harmonised System) are available to assist you in accessing published trade statistics data in the UK Global Tariff. Goods moving to and from the UK are identified by an eight-digit commodity code. These are publicly available from the UK Trade Tariff at https://www.gov.uk/trade-tariff.
The data on the import for these items, including country of export can be obtained from www.uktradeinfo.com.
If you need help or support in constructing a table from the data on uktradeinfo, please contact uktradeinfo@hmrc.gov.uk.
Asked by: Christopher Chope (Conservative - Christchurch)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what the cost to NHS England has been of reimbursing GP practices for providing services to (a) non-UK and (b) non-registered UK citizens in each of the last three years for which information is available.
Answered by Andrea Leadsom - Parliamentary Under-Secretary (Department of Health and Social Care)
General practices (GPs) are paid for providing essential services to all their patients via global sum payments, which are weighted to take patient needs into account. Therefore, there are no dedicated GP payments for providing services to non-United Kingdom or non-registered UK citizens, and the Department does not hold data on GP patient lists by nationality.